Result of General Meeting

Evgen Pharma PLC

04 April 2024

 

4 April 2024

Evgen Pharma plc

("Evgen", the "Company" or the "Group")

Result of General Meeting

and

Total Voting Rights

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces that at the General Meeting held at 10:00 a.m. at the offices of Cavendish, One Bartholomew Close, London, EC1A 7BL on 4 April 2024, the Resolutions proposed were duly passed by way of a show of hands.

Details of the proxy voting instructions lodged prior to the General Meeting for each Resolution are shown on the company's website.

Total Voting Rights

The New Ordinary Shares to be issued pursuant to the Fundraising are expected to be Admitted to trading on 5 April 2024. Following Admission of the New Ordinary Shares, the total number of Ordinary Shares in issue will be 427,346,895, with no shares held in treasury. This is the figure that may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, terms used in this announcement have the meaning given to them in the Acquisition, Fundraising and Change of Name announcement dated 19 March 2024. A further announcement shall be made regarding the Company's change of name in due course.

Enquiries

Evgen Pharma plc Dr Huw Jones, CEO  Toni Hänninen, CFO Dr Helen Kuhlman, CBO	[phone] [e-mail]
Cavendish Capital Markets (NOMAD and Broker) Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance) Nigel Birks / Harriet Ward (ECM)	[phone]
Instinctif Partners Melanie Toyne-Sewell / Jack Kincade	[phone] [e-mail]

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane. 

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicla SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of $160.5m and a double-digit royalty on sales.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com.

 

END